According to TipRanks.com, Carr is a 2-star analyst with an average return of 0.1% and a 42.4% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Gilead Sciences is a Hold with an average price target of $79.60, representing a 4.0% upside. In a report issued on June 22, Merrill Lynch also maintained a Hold rating on the stock with a $82.00 price target.
See today’s analyst top recommended stocks >>
Based on Gilead Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.55 billion and net profit of $1.55 billion. In comparison, last year the company earned revenue of $5.28 billion and had a net profit of $1.98 billion.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GILD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
Read More on GILD:
- Gilead Sets Pricing For Remdesivir Drug Candidate At $2,340 Per Patient
- Gilead To Acquire Stake in Cancer Drug Developer Pionyr For $275 Million
- Gilead Aims To Produce More Than 2 Million Remdesivir Courses By Year-End
- Indian Drugmakers Get Regulatory Nod For Generic Version Of Gilead’s Remdesivir
- Dr Reddy’s Labs Signs Licensing Agreement For Gilead’s Remdesivir